All In Biotech

Drug Trial Radar · NCT05145569

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

A Phase 2 Open-label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Patients with Metastatic Advanced Stage Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Jan 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 10, 2024

Primary completion

May 31, 2026

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Haider MahdiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
HCW Biologics
First posted
Dec 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the safety, tolerability, and anti-tumor activity of HCW9218 in combination with chemotherapy will be assessed in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy.

Conditions

  • Ovarian Cancer

Interventions

  • Carboplatin AUC 5 and paclitaxelDrug

    Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.

  • HCW9218Drug

    HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Dose Limiting Toxicities (DLT)Time frame: Up to 8 weeks
  2. Adverse Events Related to TreatmentTime frame: Up to 12 months
  3. Complete Pathologic ResponseTime frame: Up to 36 months
  4. CD8+ T-cell characterizationTime frame: Up to 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.